Skip to main content

Advertisement

SpringerLink
Log in

Social Work and Psychedelic-Assisted Therapies: Practice Considerations for Breakthrough Treatments

  • Original Paper
  • Published:
Clinical Social Work Journal Aims and scope Submit manuscript

Abstract

The re-emergence of therapeutic uses for mind-altering, psychedelic drugs has brought the field of mental health to a new frontier in research, practice, and policymaking. In the past two decades dozens of clinical trials investigating therapeutic applications of psychedelics—including MDMA, psilocybin, and ketamine—have shown promising results in the treatment of trauma-related disorders, some forms of anxiety, and depression. These substances have also garnered preliminary support from the Food and Drug Administration, which has fast-tracked their development. As the field of psychedelic science continues to grow, a serious consideration of these novel treatments in the context of social work practice and values is imperative. This paper offers a brief overview of MDMA-, psilocybin-, and ketamine-assisted treatments, and presents an initial discussion of questions pertinent to social work practice raised by their use, including: safety, efficacy, theory of change, training needs, and social justice considerations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Notes

  1. Off-label use refers to the prescription of an FDA-approved drug for a condition other than its indicated application.

References

  • Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015). Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics. Annual Review of Medicine, 66, 509–523.

    Article  PubMed  Google Scholar 

  • Abraham, A. J., Ducharme, L. J., & Roman, P. M. (2009). Counselor attitudes toward pharmacotherapies for alcohol dependence. Journal of Studies on Alcohol and Drugs, 70(4), 628–635.

    Article  PubMed  PubMed Central  Google Scholar 

  • Barone, W., Beck, J., Mitsunaga-Whitten, M., & Perl, P. (2019). Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: Qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD. Journal of Psychoactive Drugs, 51(2), 199–208.

    Article  PubMed  Google Scholar 

  • Bentley, K. J., Walsh, J., & Farmer, R. L. (2005). Social work roles and activities regarding psychiatric medication: Results of a national survey. Social Work, 50(4), 295–303.

    Article  PubMed  Google Scholar 

  • Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29, 289–299.

    Article  PubMed  Google Scholar 

  • Bokor, G., & Anderson, P. D. (2014). Ketamine: An update on its abuse. Journal of Pharmacy Practice, 27(6), 582–586.

    Article  PubMed  Google Scholar 

  • Bostwick, W. B., Boyd, C. J., Hughes, T. L., & McCabe, S. E. (2010). Dimensions of sexual orientation and the prevalence of mood and anxiety disorders in the United States. American Journal of Public Health, 100, 468–475.

    Article  PubMed  PubMed Central  Google Scholar 

  • Britt, G. C., & McCance-Katz, E. F. (2005). A brief overview of the clinical pharmacology of “club drugs”. Substance Use & Misuse, 40(9–10), 1189–1201.

    Article  Google Scholar 

  • Burgard, S. A., Cochran, S. D., & Mays, V. M. (2005). Alcohol and tobacco use patterns among heterosexually and homosexually experienced California women. Drug and Alcohol Dependence, 77, 61–70.

    Article  PubMed  PubMed Central  Google Scholar 

  • Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D. E., Kaelen, M., et al. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry, 3, 619–627.

    Article  PubMed  Google Scholar 

  • Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., et al. (2018). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology (Berl), 235, 399–408.

    Article  Google Scholar 

  • Cavnar, C. (2018, November 15). Can psychedelics “cure” gay people? Chacruna. Retrieved from https://chacruna.net/can-psychedelics-cure-gay-people/

  • Clark, R. (2011). Why don’t more people use this drug? Myths, policy, and evidence. Presented at the University of Massachusetts Clinical and Translational Science Retreat, Shrewsbury, MA.

  • Cochran, S. D., Sullivan, J. G., & Mays, V. M. (2003). Prevalence of mental disorders, psychological distress, and mental health services use among lesbian, gay, and bisexual adults in the United States. Journal of Consulting and Clinical Psychology, 71, 53–61.

    Article  PubMed  PubMed Central  Google Scholar 

  • Cochran, S. D., Mays, V. M., Alegria, M., Ortega, A. N., & Takeuchi, D. (2007). Mental health and substance use disorders among Latino and Asian American lesbian, gay, and bisexual adults. Journal of Consulting and Clinical Psychology, 75, 785–794.

    Article  PubMed  PubMed Central  Google Scholar 

  • Compass Pathways (2018). Compass pathways receives FDA breakthrough therapy designation for psilocybin therapy for treatment-resistant depression. CompassPathways.com. Retrieved from https://compasspathways.com/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/

  • Danforth, A. L., Struble, C. M., YazarKlosinski, B., & Grob, C. S. (2016). MDMAassisted therapy: A new treatment model for social anxiety in autistic adults. Progress in NeuroPsychopharmacology and Biological Psychiatry, 64, 237–249.

    Article  Google Scholar 

  • de la Torre, R., Farré, M., Roset, P. N., Pizarro, N., Abanades, S., Segura, M., et al. (2004). Human pharmacology of MDMA: Pharmacokinetics, metabolism, and disposition. Therapeutic Drug Monitoring, 26(2), 137–144.

    Article  PubMed  Google Scholar 

  • Dohrenwend, B. P., Levav, I., Shrout, P. E., Schwartz, S., Naveh, G., Link, B. G., et al. (1992). Socioeconomic status and psychiatric disorders: The causation-selection issue. Science, 255(5047), 946–952.

    Article  PubMed  Google Scholar 

  • Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., et al. (2019). Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. Journal of Psychoactive Drugs, 51(2), 189–198.

    Article  PubMed  Google Scholar 

  • Drug Enforcement Administration (DEA). (2018). Drug scheduling. Retrieved from https://www.dea.gov/drug-scheduling

  • Drug Policy Alliance. (n.d.). A brief history of the drug war. Retrieved from https://www.drugpolicy.org/issues/brief-history-drug-war

  • Dunlop, D. D., Song, J., Lyons, J. S., Manheim, L. M., & Chang, R. W. (2003). Racial/ethnic differences in rates of depression among preretirement adults. American Journal of Public Health, 93(11), 1945–1952.

    Article  PubMed  PubMed Central  Google Scholar 

  • Feder, A., Parides, M., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., et al. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry, 71(6), 681–688.

    Article  PubMed  Google Scholar 

  • Foa, E. B., Keane, T. M., Friedman, M. J., & Cohen, J. (2009). Effective treatments for PTSD: Practice guidelines from the International Society for Traumatic Stress Studies. New York: Guilford Press.

    Google Scholar 

  • Food and Drug Administration. (2019a). Expanded access. Retrieved from https://www.fda.gov/news-events/public-health-focus/expanded-access

  • Food and Drug Administration. (2019b). Frequently Asked Questions: Breakthrough Therapies. Retrieved from https://www.fda.gov/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/frequently-asked-questions-breakthrough-therapies

  • Food and Drug Administration. (2019c). FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified

  • Ford, J. G., Howerton, M. W., Lai, G. Y., Gary, T. L., Bolen, S., Gibbons, M. C., et al. (2007). Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic review. Cancer, 112(2), 228–242.

    Article  Google Scholar 

  • Galanter, M. (2018). Combining medically assisted treatment and twelve-step programming: A perspective and review. The American Journal of Drug and Alcohol Abuse, 44(2), 151–159.

    Article  PubMed  Google Scholar 

  • Gilman, S. E., Cochran, S. D., Mays, V. M., Hughes, M., Ostrow, D., & Kessler, R. C. (2001). Risk of psychiatric disorders among individuals reporting same-sex sexual partners in the National Comorbidity Survey. American Journal of Public Health, 91, 933–939.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ginsberg, N. L. & Lourido, A. (2019). Statement: Considerations for the regulation and decriminalization of psychedelic substances. Retrieved from https://maps.org/news/media/7731-considerations-for-the-regulation-decriminalization-of-psychedelic-substances

  • Greer, G., & Tolbert, R. (1998). A method of conducting therapeutic sessions with MDMA. Journal of Psychoactive Drugs, 30(4), 371–379.

    Article  PubMed  Google Scholar 

  • Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl), 187(3), 268–283.

    Article  Google Scholar 

  • Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30, 1181–1197.

    Article  PubMed  Google Scholar 

  • Grinspoon, L., & Doblin, R. (2001). Psychedelics as catalysts of insight-oriented psychotherapy. Social Research, 68(3), 676–695.

    Google Scholar 

  • Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., et al. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry, 68, 71–78.

    Article  PubMed  Google Scholar 

  • Han, Y., Chen, J., Zou, D., Zheng, P., Li, Q., Wang, H., et al. (2016). Efficacy of ketamine in the rapid treatment of major depressive disorder: A meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatric Disease and Treatment, 12, 2859–2867.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hass, A. P., Rogers, P. L., & Herman J. L. (2014). Suicide attempts among transgender and gender non-conforming adults: Findings of the National Transgender Discrimination Survey. Retrieved from https://williamsinstitute.law.ucla.edu/wp-content/uploads/AFSP-Williams-Suicide-Report-Final.pdf

  • Hayley, S. & Littlejohn, D. (2013). Neuroplasticity and the next wave of antidepressant strategies. Frontiers in Cellular Neuroscience. https://doi.org/10.3389/fncel.2013.00218.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hoffman, A. (1980). LSD: My problem child. New York, NY: McGraw Hill.

    Google Scholar 

  • Hutchison, C., & Bressi, S. (2018). MDMA-Assisted psychotherapy for posttraumatic stress disorder: Implications for social work practice and research. Clinical Social Work Journal. https://doi.org/10.1007/s10615-018-0676-3.

    Article  Google Scholar 

  • Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J., Ricahrds, E. M., & Zarate, C. A. (2014). A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Biopolar Disorders, 17(4), 438–443.

    Article  Google Scholar 

  • Jerome, L., Schuster, S., & Yazar-Klosinski, B. (2013). Can MDMA play a role in the treatment of substance abuse? Current Drug Abuse Reviews, 6(1), 54–62.

    Article  PubMed  Google Scholar 

  • Johansen, P.-Ø., & Krebs, T. S. (2015). Psychedelics not linked to mental health problems or suicidal behavior: A population study. Journal of Psychopharmacology, 29(3), 270–279.

    Article  PubMed  Google Scholar 

  • Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse, 43(1), 55–60.

    Article  PubMed  Google Scholar 

  • Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 142, 143–166.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ketamine Advocacy Network. (2018). How much does ketamine therapy cost? Retrieved from https://www.ketamineadvocacynetwork.org/cost/

  • Khantzian, E. J. (2014). A psychodynamic perspective on the efficacy of 12-step programs. Alcoholism Treatment Quarterly, 32(2–3), 225–236.

    Article  Google Scholar 

  • Knudsen, H. K., Ducharme, L. J., Roman, P. M., & Link, T. J. (2005). Buprenorphine diffusion: Attitudes of substance abuse treatment counselors. Journal of Substance Abuse Treatment, 29, 95–106.

    Article  PubMed  Google Scholar 

  • Knudsen, H. K., Ducharme, L. J., & Roman, P. M. (2007). Research network involvement and addiction treatment center staff: Counselor attitudes towards buprenorphine. American Journal on Addictions, 16, 365–371.

    Article  PubMed  Google Scholar 

  • Kolp, E., Friedman, H., Krupitsky, E., Jansen, K., Sylvester, M., Young, M. S., et al. (2014). Ketamine psychedelic psychotherapy: Focus on its pharmacology, phenomenology, and clinical applications. International Journal of Transpersonal Studies, 33(2), 84–140.

    Article  Google Scholar 

  • Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002). Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up. Journal of Substance Abuse Treatment, 23, 273–283.

    Article  PubMed  Google Scholar 

  • McGuire, T. G., & Miranda, J. (2008). Racial and ethnic disparities in mental health care: Evidence and policy implications. Health Affairs, 27(2), 393–403.

    Article  PubMed  Google Scholar 

  • Michaels, T. I., Purdon, J., Collins, A., & Williams, M. T. (2018). Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. BMC Psychiatry, 18, 245.

    Article  PubMed  PubMed Central  Google Scholar 

  • Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011). The safety and efficacy of ± 3,4methylenedioxymethamphetamine assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. Journal of Psychopharmacology, 25(4), 439–452.

    Article  PubMed  Google Scholar 

  • Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar-Klosinski, B., et al. (2013). Durability of improvement in posttraumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4 methylenedioxymethamphetamineassisted psychotherapy: A prospective long term followup study. Journal of Psychopharmacology, 27(1), 28–39.

    Article  PubMed  Google Scholar 

  • Mithoefer, M. C., Mithoefer, A., Jerome, L., Ruse, J., Doblin, R., Gibson, E., et al. (2017). A manual for MDMA-assisted psychotherapy in the treatment of PTSD. Retrieved from https://s3uswest1.amazonaws.com/mapscontent/researcharchive/mdma/TreatmentManual_MDMAAssistedPsychotherapyVersion+8.1_22+Aug

  • Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., et al. (2018). 3, 4methylenedioxymethamphetamine (MDMA)assisted psychotherapy for posttraumatic stress disorder in military veterans, firefighters, and police officers: A randomised, doubleblind, doseresponse, phase 2 clinical trial. The Lancet Psychiatry, 5(6), 486–497.

    Article  PubMed  Google Scholar 

  • Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry, 67(11), 1735–1740.

    Article  PubMed  Google Scholar 

  • Multidisciplinary Association for Psychedelic Studies (MAPS). (2017a). MDMA Investigational Brochure. Retrieved from maps.org/research/mdma/mdma-%20research-%20timeline/104-%20other-mdma-%20resources/%205400-%20mdma-investigator-s-brochure-and-fda-annual-reportandItemid=485

  • Multidisciplinary Association for Psychedelic Studies (MAPS). (2017b). Press release: FDA grants breakthrough therapy designation for MDMA assisted psychotherapy for PTSD, agrees on special protocol assessment for phase 3 trials. Retrieved from https://www.maps.org/news/media/6786pressreleasefdagrantsbreakthroughtherapydesignationformdmaassistedpsychotherapyforptsd,agreesonspecialprotocolassessmentforphase3trials

  • Multidisciplinary Association for Psychedelic Studies (MAPS). (2019a). Expanded access training update: April 2019. Retrieved from https://maps.org/research/mdma/training-protocol/news/7693-expanded-access-training-update-april-2019

  • Multidisciplinary Association for Psychedelic Studies (MAPS). (2019b). MDMA therapy training for communities of color and psychedelic medicine and cultural trauma community workshop: 8-day conference. Retrieved from https://maps.org/mdma-poc-training

  • Ogden, P., Minton, K., & Pain, C. (2006). Trauma and the body: A sensorimotor approach to psychotherapy. New York: W.W. Norton.

    Google Scholar 

  • Platt, A. (2014). Suboxone: A harm reduction approach. Journal of Alcoholism & Drug Dependence, 2(5), 1000.

    Google Scholar 

  • Ramos, M. A., Boyd, J. W., & Alpert, M. D. (2019). “Opinion: The new ketamine-based antidepressant is a rip-off”. Vice. Retrieved from https://www.vice.com/en_us/article/pajkjy/opinion-the-new-ketamine-based-antidepressant-is-a-rip-off

  • Roberts, A. L., Gilman, S. E., Breslau, J., Breslau, N., & Koenen, K. C. (2010). Race/ethnic differences in exposure to traumatic events, development of post-traumatic stress disorder, and treatment-seeking for post-traumatic stress disorder in the United States. Psychological Medicine, 41(1), 71–83.

    Article  PubMed  PubMed Central  Google Scholar 

  • Robinson, S. M., & Adinoff, B. (2018). The mixed message behind “medication-assisted treatment” for substance use disorder. The American Journal of Drug and Alcohol Abuse, 44(2), 147–150. https://doi.org/10.1080/00952990.2017.1362419.

    Article  PubMed  Google Scholar 

  • Roquet, S., Favreau, P., Ocana, R., & Velasco, M. (1971). The existential through psychodisleptics—a new psychotherapy. Mexico City, Mexico: Asociación Albert Schweitzer.

    Google Scholar 

  • Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30, 1165–1180.

    Article  PubMed  Google Scholar 

  • Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018). Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology, 142, 200–218.

    Article  PubMed  Google Scholar 

  • Serafini, G., Howland, R. H., Rovedi, R., Girardi, P., & Amore, M. (2014). The role of ketamine in treatment-resistantdepression: A systematic review. Current Neuropharmacology, 12(5), 444–461.

    Article  PubMed  PubMed Central  Google Scholar 

  • Silverman, E. (2019). J&J’s new esketamine drug for depression may solve an unmet need, but may not be cost-effective. Stat. Retrieved from https://www.statnews.com/pharmalot/2019/03/22/antidepressants-cost-effective-johnson-and-johnson/

  • Singh, I., Morgan, C., Curran, V., Nutt, D., Schlag, A., & McShane, R. (2017). Ketamine treatment for depression: Opportunities for clinical innovation and ethical foresight. The Lancet, 4(5), 419–426.

    PubMed  Google Scholar 

  • Slopen, N., Shonkoff, J. P., Albert, M. A., Yoshikawa, H., Jacobs, A., Stoltz, R., et al. (2016). Racial disparities in child adversity in the U.S.: Interactions with family immigration history and income. American Journal of Preventive Medicine, 50(1), 47–56.

    Article  PubMed  Google Scholar 

  • Turillazzi, E., Riezzo, I., Neri, M., Bello, S., & Fineschi, V. (2010). MDMA toxicity and pathological consequences: A review about experimental data and autopsy findings. Retrieved from https://www.ingentaconnect.com/content/ben/cpb/

  • U.S. Department of Veterans Affairs. (2017). Cognitive processing therapy for PTSD. Retrieved from https://www.ptsd.va.gov/public/treatment/therapymed/cognitive_processing_therapy.asp

  • U.S. Food and Drug Administration. (2018). FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. Retrieved from https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm632761.htm

  • U.S. Food and Drug Administration. (2019). Fact sheet: Breakthrough therapies. Retrieved from https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDASIA/ucm329491.htm

  • Vandiver, V. (Ed.). (2013). Best practices in Community Mental Health. New York: Oxford University Press.

    Google Scholar 

  • Wakeman, S. E., & Rich, J. D. (2018). Barriers to medications for addiction treatment: How stigma kills. Substance Use & Misuse, 53(2), 330–333.

    Article  Google Scholar 

  • Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. Journal of Humanistic Psychology, 57(5), 520–564.

    Article  Google Scholar 

  • Yasgur, B. S. (2019). Ketamine: A promising novel therapy for anxiety and pTSD. Psychiatry Advisor. Retrieved from https://www.psychiatryadvisor.com/home/topics/anxiety/ketamine-a-promising-novel-therapy-for-anxiety-and-ptsd/

  • Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, N., Luckenbaugh, D. A., et al. (2006). A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63, 856–864.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rutgers School of Social Work, 120 Albany Street, New Brunswick, NJ, 08901, USA

    Courtney Hutchison

  2. Bryn Mawr College Graduate School of Social Work and Social Research, 300 Airdale Rd, Bryn Mawr, PA, 19010, USA

    Sara Bressi

Authors
  1. Courtney Hutchison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara Bressi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Courtney Hutchison.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

Research on human subjects were not involved in this manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hutchison, C., Bressi, S. Social Work and Psychedelic-Assisted Therapies: Practice Considerations for Breakthrough Treatments. Clin Soc Work J 49, 356–367 (2021). https://doi.org/10.1007/s10615-019-00743-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10615-019-00743-x

Keywords

Search

Navigation